OptimizeRx
OPRX
98 hedge funds and large institutions have $180M invested in OptimizeRx in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 15 closing their positions.
691% more call options, than puts
Call options by funds: $3.87M | Put options by funds: $489K
77% more capital invested
Capital invested by funds: $102M → $180M (+$78.1M)
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
4% more funds holding
Funds holding: 94 → 98 (+4)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.29% less ownership
Funds ownership: 78.55% → 69.26% (-9.3%)
Top Buyers
| 1 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$9.11M |
| 2 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$1.29M |
| 3 |
Morgan Stanley
New York
|
+$1.04M |
| 4 |
GIPM
G2 Investment Partners Management
New York
|
+$927K |
| 5 |
Renaissance Technologies
New York
|
+$886K |
Top Sellers
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.28M |
| 2 |
AC
Avenir Corporation
Alexandria,
Virginia
|
-$2.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.59M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.58M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.32M |
OPRX Hedge Fund Activity: Q4 2023 in Review
98 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q4 2023, worth a combined $180M — up 77% from $102M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OPRX positions and 15 closed out — a net gain of 6 holders — while 32 added to existing stakes and 30 trimmed.
The largest buyer was Divisadero Street Capital Management, opening a new position worth an estimated $9.11M. The largest seller was First Light Asset Management, cutting an estimated $7.28M.
- 98 institutional investors held OptimizeRx (OPRX) as of Q4 2023, up from 94 in Q3 2023.
- Funds reported $180M of OptimizeRx stock for Q4 2023, up 77% quarter-over-quarter.
- 21 funds opened new OptimizeRx positions in Q4 2023 and 15 closed out, a net change of +6 holders.
- The largest OptimizeRx buyer in Q4 2023 was Divisadero Street Capital Management, an estimated $9.11M added.
- The largest OptimizeRx seller in Q4 2023 was First Light Asset Management, an estimated $7.28M sold.
Based on aggregated 13F filings for Q4 2023.